Vascular and Interstitial Biology of Tumors

Abeloff's Clinical Oncology: Fifth Edition

Volumn , Issue , 2013, Pages 108-126.e6

  Jain, Rakesh K ^a,b   Chauhan, Vikash P ^b   Duda, Dan G ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84944573723     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-1-4557-2865-7.00008-4     Document Type: Chapter

References (262)

1. Goldman E The growth of malignant disease in man and the lower animals with special reference to the vascular system. Lancet 1907, 2:1236-1240.
2. Algire GH, Chalkley HW Vascular reactions of normal and malignant tissues in vivo. I. Vascular reactions of mice to wounds and to normal and neoplastic transplants. J Natl Cancer Inst 1945, 6:73-85.
3. Ide AG, Baker NH, Warren SL Vascularization of the Brown-Pearce rabbit epithelioma transplant as seen in the transplant ear chamber. Am J Radiol 1939, 42:891-899.
4. Jain RK, Munn LL, Fukumura D Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002, 2:266-276.
5. Jain RK, Schlenger K, Hockel M, et al. Quantitative angiogenesis assays: progress and problems. Nat Med 1997, 3:1203-1208.
6. Helmlinger G, Netti PA, Lichtenbeld HC, et al. Solid stress inhibits the growth of multicellular tumor spheroids. Nat Biotechnol 1997, 15:778-783.
7. Folkman J Tumor angiogenesis: therapeutic implications. N Engl J Med 1971, 285:1182-1186.
8. Gullino PM Angiogenesis and oncogenesis. J Natl Cancer Inst 1978, 61:639-643.
9. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004, 350:2335-2342.
10. Carmeliet P Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
11. Carmeliet P, Jain RK Molecular mechanisms and clinical applications of angiogenesis. Nature 2011, 473:298-307.
12. Jain RK, Carmeliet PF Vessels of death or life. Sci Am 2001, 285:38-45.
13. Bouck N, Stellmach V, Hsu SC How tumors become angiogenic. Adv Cancer Res 1996, 69:135-174.
14. Hanahan D, Weinberg RA Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
15. Dvorak HF Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002, 20:4368-4380.
16. Patan S, Munn LL, Jain RK Intussusceptive microvascular growth in a human colon adenocarcinoma xenograft: a novel mechanism of tumor angiogenesis. Microvasc Res 1996, 51:260-272.
17. Patan S, Munn LL, Tanda S, et al. Vascular morphogenesis and remodeling in a model of tissue repair: blood vessel formation and growth in the ovarian pedicle after ovariectomy. Circ Res 2001, 89:723-731.
18. Patan S, Tanda S, Roberge S, et al. Vascular morphogenesis and remodeling in a human tumor xenograft: blood vessel formation and growth after ovariectomy and tumor implantation. Circ Res 2001, 89:732-739.
19. Jain RK Molecular regulation of vessel maturation. Nat Med 2003, 9:685-693.
20. Duda DG, Cohen KS, Kozin SV, et al. Evidence for incorporation of bone marrow-derived endothelial cells into perfused blood vessels in tumors. Blood 2006, 107:2774-2776.
21. Isner JM Myocardial gene therapy. Nature 2002, 415:234.
22. Rafii S, Lyden D, Benezra R, et al. Vascular and haematopoietic stem cells: novel targets for anti-angiogenesis therapy?. Nat Rev Cancer 2002, 2:826-835.
23. Sajithlal GB, McGuire TF, Lu J, et al. Endothelial-like cells derived directly from human tumor xenografts. Int J Cancer 2010, 127:2268-2278.
24. Ricci-Vitiani L, Pallini R, Biffoni M, et al. Tumour vascularization via endothelial differentiation of glioblastoma stem-like cells. Nature 2010, 468:824-828.
25. Soda Y, Marumoto T, Friedmann-Morvinski D, et al. Feature Article: Transdifferentiation of glioblastoma cells into vascular endothelial cells. Proc Natl Acad Sci U S A 2011, 108:4274-4280.
26. Wang R, Chadalavada K, Wilshire J, et al. Glioblastoma stem-like cells give rise to tumour endothelium. Nature 2010, 468:829-833.
27. Kozin SV, Duda DG, Munn LL, et al. Neovascularization after irradiation: what is the source of newly formed vessels in recurring tumors?. J Natl Cancer Inst 2012, 104:899-905.
28. Ergun S, Hohn HP, Kilic N, et al. Endothelial and hematopoietic progenitor cells (EPCs and HPCs): hand in hand fate determining partners for cancer cells. Stem Cell Rev 2008, 4:169-177.
29. Aicher A, Rentsch M, Sasaki K, et al. Nonbone marrow-derived circulating progenitor cells contribute to postnatal neovascularization following tissue ischemia. Circ Res 2007, 100:581-589.
30. Kozin SV, Duda DG, Munn LL, et al. Is vasculogenesis crucial for the regrowth of irradiated tumours?. Nat Rev Cancer 2011, 11:532.
31. Dvorak HF, Nagy JA, Feng D, et al. Tumor Architecture and Targeted Delivery. Radioimmunotherapy of Cancer 2000, 107-135. Marcel Dekker, Inc., New York. P.G. Abrams, A.R. Fritzberg (Eds.).
32. Ferrara N, Gerber HP, LeCouter J The biology of VEGF and its receptors. Nat Med 2003, 9:669-676.
33. Melder RJ, Koenig GC, Witwer BP, et al. During angiogenesis, vascular endothelial growth factor and basic fibroblast growth factor regulate natural killer cell adhesion to tumor endothelium. Nat Med 1996, 2:992-997.
34. Casanovas O, Hicklin DJ, Bergers G, et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
35. Fidler IJ Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Instit 2001, 93:1040-1041.
36. Yoshiji H, Harris SR, Thorgeirsson UP Vascular endothelial growth factor is essential for initial but not continued in vivo growth of human breast carcinoma cells. Cancer Res 1997, 57:3924-3928.
37. Jain RK, Duda DG, Willett CG, et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol 2009, 6:327-338.
38. LeCouter J, Ferrara N EG-VEGF and Bv8. a novel family of tissue-selective mediators of angiogenesis, endothelial phenotype, and function. Trends Cardiovasc Med 2003, 13:276-282.
39. Yancopoulos GD, Davis S, Gale NW, et al. Vascular-specific growth factors and blood vessel formation. Nature 2000, 407:242-248.
40. Maeshima Y, Sudhakar A, Lively JC, et al. Tumstatin, an endothelial cell-specific inhibitor of protein synthesis. Science 2002, 295:140-143.
41. O'Reilly MS, Boehm T, Shing Y, et al. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88:277-285.
42. O'Reilly MS, Holmgren L, Shing Y, et al. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
43. Kalluri R Basement membranes: structure, assembly and role in tumour angiogenesis. Nat Rev Cancer 2003, 3:422-433.
44. Fukumura D, Xu L, Chen Y, et al. Hypoxia and acidosis independently up-regulate vascular endothelial growth factor transcription in brain tumors in vivo. Cancer Res 2001, 61:6020-6024.
45. Garkavtsev I, Kozin SV, Chernova O, et al. The candidate tumour suppressor protein ING4 regulates brain tumour growth and angiogenesis. Nature 2004, 428:328-332.
46. Kerbel RS Tumor angiogenesis. N Engl J Med 2008, 358:2039-2049.
47. Xu L, Fukumura D, Jain RK Acidic extracellular pH induces vascular endothelial growth factor (VEGF) in human glioblastoma cells via ERK1/2 MAPK signaling pathway: mechanism of low pH-induced VEGF. J Biol Chem 2002, 277:11368-11374.
48. Brown EB, Campbell RB, Tsuzuki Y, et al. In vivo measurement of gene expression, angiogenesis and physiological function in tumors using multiphoton laser scanning microscopy. Nat Med 2001, 7:864-868.
49. Fukumura D, Jain RK Role of nitric oxide in angiogenesis and microcirculation in tumors. Cancer Metastasis Rev 1998, 17:77-89.
50. Helmlinger G, Endo M, Ferrara N, et al. Formation of endothelial cell networks. Nature 2000, 405:139-141.
51. Tsuzuki Y, Fukumura D, Oosthuyse B, et al. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1alpha-> hypoxia response element-> VEGF cascade differentially regulates vascular response and growth rate in tumors. Cancer Res 2000, 60:6248-6252.
52. Blouw B, Song H, Tihan T, et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003, 4:133-146.
53. Dellian M, Helmlinger G, Yuan F, et al. Fluorescence ratio imaging of interstitial pH in solid tumours: effect of glucose on spatial and temporal gradients. Br J Cancer 1996, 74:1206-1215.
54. Fukumura D, Yuan F, Monsky WL, et al. Effect of host microenvironment on the microcirculation of human colon adenocarcinoma. Am J Pathol 1997, 151:679-688.
55. Gohongi T, Fukumura D, Boucher Y, et al. Tumor-host interactions in the gallbladder suppress distal angiogenesis and tumor growth: involvement of transforming growth factor beta1. Nat Med 1999, 5:1203-1208.
56. Hobbs SK, Monsky WL, Yuan F, et al. Regulation of transport pathways in tumor vessels: role of tumor type and microenvironment. Proc Natl Acad Sci U S A 1998, 95:4607-4612.
57. Monsky WL, Mouta Carreira C, Tsuzuki Y, et al. Role of host microenvironment in angiogenesis and microvascular functions in human breast cancer xenografts: mammary fat pad versus cranial tumors. Clin Cancer Res 2002, 8:1008-1013.
58. Tsuzuki Y, Mouta Carreira C, Bockhorn M, et al. Pancreas microenvironment promotes VEGF expression and tumor growth: novel window models for pancreatic tumor angiogenesis and microcirculation. Lab Invest 2001, 81:1439-1451.
59. Yuan F, Salehi HA, Boucher Y, et al. Vascular permeability and microcirculation of gliomas and mammary carcinomas transplanted in rat and mouse cranial windows. Cancer Res 1994, 54:4564-4568.
60. Izumi Y, Xu L, di Tomaso E, et al. Tumour biology: herceptin acts as an anti-angiogenic cocktail. Nature 2002, 416:279-280.
61. Jain RK, Safabakhsh N, Sckell A, et al. Endothelial cell death, angiogenesis, and microvascular function after castration in an androgen-dependent tumor: role of vascular endothelial growth factor. Proc Natl Acad Sci U S A 1998, 95:10820-10825.
62. Jain RK Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 2005, 307:58-62.
63. Jain RK Taming vessels to treat cancer. Sci Am 2008, 298:56-63.
64. Ramanujan S, Koenig GC, Padera TP, et al. Local imbalance of proangiogenic and antiangiogenic factors: a potential mechanism of focal necrosis and dormancy in tumors. Cancer Res 2000, 60:1442-1448.
65. Baish JW, Jain RK Fractals and cancer. Cancer Res 2000, 60:3683-3688.
66. Gazit Y, Berk DA, Leunig M, et al. Scale-Invariant Behavior and Vascular Network Formation in Normal and Tumor-Tissue. Phys Rev Lett 1995, 75:2428-2431.
67. Gazit Y, Baish JW, Safabakhsh N, et al. Fractal characteristics of tumor vascular architecture during tumor growth and regression. Microcirculation 1997, 4:395-402.
68. McDonald DM, Choyke PL Imaging of angiogenesis: from microscope to clinic. Nat Med 2003, 9:713-725.
69. Jain RK Determinants of tumor blood flow: a review. Cancer Res 1988, 48:2641-2658.
70. Less JR, Posner MC, Skalak TC, et al. Geometric resistance and microvascular network architecture of human colorectal carcinoma. Microcirculation 1997, 4:25-33.
71. Less JR, Skalak TC, Sevick EM, et al. Microvascular architecture in a mammary carcinoma: branching patterns and vessel dimensions. Cancer Research 1991, 51:265-273.
72. Jain RK, Munn LL Leaky vessels? Call Angl1!. Nat Med 2000, 6:131-132.
73. Goel S, Duda DG, Xu L, et al. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev 2011, 91:1071-1121.
74. Goel S, Fukumura D, Jain RK Normalization of the tumor vasculature through oncogenic inhibition: An emerging paradigm in tumor biology. Proc Natl Acad Sci U S A 2012, 109(20):E1214.
75. Huang Y, Yuan J, Righi E, et al. Vascular normalizing dose of antiangiogenic treatment reprograms the immunosuppressive tumor microenvironment and enhances immunotherapy. Proc Natl Acad Sci U S A 2012, 109(43):17561-17566.
76. Kadambi A, Mouta Carreira C, Yun CO, et al. Vascular endothelial growth factor (VEGF)-C differentially affects tumor vascular function and leukocyte recruitment: role of VEGF-receptor 2 and host VEGF-A. Cancer Res 2001, 61:2404-2408.
77. Koike C, McKee TD, Pluen A, et al. Solid stress facilitates spheroid formation: potential involvement of hyaluronan. Br J Cancer 2002, 86:947-953.
78. Stylianopoulos T, Martin JD, Chauhan VP, et al. Causes, consequences and remedies for growth-induced solid stress in murine and human tumors. Proc Natl Acad Sci U S A 2012, 109(38):15101-15108.
79. Griffon-Etienne G, Boucher Y, Brekken C, et al. Taxane-induced apoptosis decompresses blood vessels and lowers interstitial fluid pressure in solid tumors: clinical implications. Cancer Res 1999, 59:3776-3782.
80. Padera TP, Stoll BR, Tooredman JB, et al. Pathology: cancer cells compress intratumour vessels. Nature 2004, 427:695.
81. Jacobetz MA, Chan DS, Neesse A, et al. Hyaluronan impairs vascular function and drug delivery in a mouse model of pancreatic cancer. Gut 2012.
82. Sevick EM, Jain RK Geometric resistance to blood flow in solid tumors perfused ex vivo: effects of tumor size and perfusion pressure. Cancer Research 1989, 49:3506-3512.
83. Sevick EM, Jain RK Viscous resistance to blood flow in solid tumors: effect of hematocrit on intratumor blood viscosity. Cancer Res 1989, 49:3513-3519.
84. Sevick EM, Jain RK Effect of red blood cell rigidity on tumor blood flow: increase in viscous resistance during hyperglycemia. Cancer Research 1991, 51:2727-2730.
85. Jain RK, Ward-Hartley KA Tumor blood flow: characterization, modifications and role in hyperthermia. IEEE Transactions in Sonics and Ultrasonics; Special Issue on Hyperthermia 1984, SU-31:504-526.
86. Vaupel P, Kallinowski F, Okunieff P Blood flow, oxygen and nutrient supply, and metabolic microenvironment of human tumors: a review. Cancer Res 1989, 49:6449-6465.
87. Endrich B, Reinhold HS, Gross JF, et al. Tissue perfusion inhomogeneity during early tumor growth in rats. J Natl Cancer Inst 1979, 62:387-395.
88. Jain RK, Forbes NS Can engineered bacteria help control cancer?. Proc Natl Acad Sci U S A 2001, 98:14748-14750.
89. Leunig M, Yuan F, Menger MD, et al. Angiogenesis, microvascular architecture, microhemodynamics, and interstitial fluid pressure during early growth of human adenocarcinoma LS174T in SCID mice. Cancer Res 1992, 52:6553-6560.
90. Brizel DM, Klitzman B, Cook JM, et al. A comparison of tumor and normal tissue microvascular hematocrits and red cell fluxes in a rat window chamber model. Intl J Rad Oncol Biol Phys 1993, 25:269-276.
91. Baish JW, Netti PA, Jain RK Transmural coupling of fluid flow in microcirculatory network and interstitium in tumors. Microvasc Res 1997, 53:128-141.
92. Netti PA, Roberge S, Boucher Y, et al. Effect of transvascular fluid exchange on pressure-flow relationship in tumors: a proposed mechanism for tumor blood flow heterogeneity. Microvasc Res 1996, 52:27-46.
93. Mollica F, Jain RK, Netti PA A model for temporal heterogeneities of tumor blood flow. Microvasc Res 2003, 65:56-60.
94. Park MS, Klotz E, Kim MJ, et al. Perfusion CT: noninvasive surrogate marker for stratification of pancreatic cancer response to concurrent chemo- and radiation therapy. Radiology 2009, 250:110-117.
95. Sorensen AG, Emblem KE, Polaskova P, et al. Increased survival of glioblastoma patients who respond to antiangiogenic therapy with elevated blood perfusion. Cancer Res 2012, 72:402-407.
96. Morikawa S, Baluk P, Kaidoh T, et al. Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors. Am J Pathol 2002, 160:985-1000.
97. Dolmans DE, Kadambi A, Hill JS, et al. Vascular accumulation of a novel photosensitizer, MV6401, causes selective thrombosis in tumor vessels after photodynamic therapy. Cancer Res 2002, 62:2151-2156.
98. Huang X, Molema G, King S, et al. Tumor infarction in mice by antibody-directed targeting of tissue factor to tumor vasculature. Science 1997, 275:547-550.
99. Ruoslahti E Specialization of tumor vasculature. Nature Reviews Cancer 2002, 2:83-90.
100. Jain RK Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy. Nat Med 2001, 7:987-989.
101. Chauhan VP, Stylianopoulos T, Boucher Y, et al. Delivery of molecular and nanoscale medicine to tumors: transport barriers and strategies. Annu Rev Chem Biomol Eng 2011, 2:281-298.
102. Jain RK Transport of molecules across tumor vasculature. Cancer Metastasis Rev 1987, 6:559-593.
103. Hashizume H, Baluk P, Morikawa S, et al. Openings between defective endothelial cells explain tumor vessel leakiness. Am J Pathol 2000, 156:1363-1380.
104. Endo M, Jain RK, Witwer B, et al. Water channel (aquaporin 1) expression and distribution in mammary carcinomas and glioblastomas. Microvasc Res 1999, 58:89-98.
105. Gerlowski LE, Jain RK Microvascular permeability of normal and neoplastic tissues. Microvasc Res 1986, 31:288-305.
106. Lichtenbeld HC, Yuan F, Michel CC, et al. Perfusion of single tumor microvessels: application to vascular permeability measurement. Microcirculation 1996, 3:349-357.
107. Sevick EM, Jain RK Measurement of capillary filtration coefficient in a solid tumor. Cancer Res 1991, 51:1352-1355.
108. Yuan F, Leunig M, Berk DA, et al. Microvascular permeability of albumin, vascular surface area, and vascular volume measured in human adenocarcinoma LS174T using dorsal chamber in SCID mice. Microvasc Res 1993, 45:269-289.
109. Yuan F, Dellian M, Fukumura D, et al. Vascular permeability in a human tumor xenograft: molecular size dependence and cutoff size. Cancer Res 1995, 55:3752-3756.
110. Dreher MR, Liu W, Michelich CR, et al. Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers. J Natl Cancer Inst 2006, 98:335-344.
111. Chauhan VP, Stylianopoulos T, Martin JD, et al. Normalization of tumour blood vessels improves the delivery of nanomedicines in a size-dependent manner. Nat Nanotechnol 2012, 7:383-388.
112. Chauhan VP, Popovic Z, Chen O, et al. Fluorescent nanorods and nanospheres for real-time in vivo probing of nanoparticle shape-dependent tumor penetration. Angew Chem Int Ed Engl 2011, 50:11417-11420.
113. Campbell RB, Fukumura D, Brown EB, et al. Cationic charge determines the distribution of liposomes between the vascular and extravascular compartments of tumors. Cancer Res 2002, 62:6831-6836.
114. Dellian M, Yuan F, Trubetskoy VS, et al. Vascular permeability in a human tumour xenograft: molecular charge dependence. Br J Cancer 2000, 82:1513-1518.
115. Stylianopoulos T, Soteriou K, Fukumura D, et al. Cationic Nanoparticles Have Superior Transvascular Flux into Solid Tumors: Insights from a Mathematical Model. Ann Biomed Eng 2012.
116. Thurston G, McLean JW, Rizen M, et al. Cationic liposomes target angiogenic endothelial cells in tumors and chronic inflammation in mice. J Clin Invest 1998, 101:1401-1413.
117. Monsky WL, Fukumura D, Gohongi T, et al. Augmentation of transvascular transport of macromolecules and nanoparticles in tumors using vascular endothelial growth factor. Cancer Res 1999, 59:4129-4135.
118. Yuan F, Chen Y, Dellian M, et al. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc Natl Acad Sci U S A 1996, 93:14765-14770.
119. Bockhorn M, Roberge S, Sousa C, et al. Differential gene expression in metastasizing cells shed from kidney tumors. Cancer Res 2004, 64:2469-2473.
120. Chang YS, di Tomaso E, McDonald DM, et al. Mosaic blood vessels in tumors: Frequency of cancer cells in contact with flowing blood. Proc Natl Acad Sci U S A 2000, 97:14608-14613.
121. Gullino PM Techniques in tumor pathophysiology. Methods in Cancer Research 1970, 45-92. Academic Press, New York. H. Busch (Ed.).
122. Swartz MA, Kristensen CA, Melder RJ, et al. Cells shed from tumours show reduced clonogenicity, resistance to apoptosis, and in vivo tumorigenicity. Br J Cancer 1999, 81:756-759.
123. Duda DG, Duyverman AM, Kohno M, et al. Malignant cells facilitate lung metastasis by bringing their own soil. Proc Natl Acad Sci U S A 2010, 107:21677-21682.
124. Jain RK, Koenig GC, Dellian M, et al. Leukocyte-endothelial adhesion and angiogenesis in tumors. Cancer Metastasis Rev 1996, 15:195-204.
125. Melder RJ, Munn LL, Yamada S, et al. Selectin- and integrin-mediated T-lymphocyte rolling and arrest on TNF-alpha-activated endothelium: augmentation by erythrocytes. Biophys J 1995, 69:2131-2138.
126. Melder RJ, Yuan J, Munn LL, et al. Erythrocytes enhance lymphocyte rolling and arrest in vivo. Microvasc Res 2000, 59:316-322.
127. Migliorini C, Qian Y, Chen H, et al. Red blood cells augment leukocyte rolling in a virtual blood vessel. Biophys J 2002, 83:1834-1841.
128. Munn LL, Melder RJ, Jain RK Role of erythrocytes in leukocyte-endothelial interactions: mathematical model and experimental validation. Biophys J 1996, 71:466-478.
129. Yuan J, Melder RJ, Jain RK, et al. Lateral view flow system for studies of cell adhesion and deformation under flow conditions. Biotechniques 2001, 30:388-394.
130. Melder RJ, Kristensen CA, Munn LL, et al. Modulation of A-NK cell rigidity: In vitro characterization and in vivo implications for cell delivery. Biorheology 2001, 38:151-159.
131. Al-Mehdi AB, Tozawa K, Fisher AB, et al. Intravascular origin of metastasis from the proliferation of endothelium-attached tumor cells: a new model for metastasis. Nat Med 2000, 6:100-102.
132. Fukumura D, Salehi HA, Witwer B, et al. Tumor necrosis factor alpha-induced leukocyte adhesion in normal and tumor vessels: effect of tumor type, transplantation site, and host strain. Cancer Res 1995, 55:4824-4829.
133. Dellian M, Witwer BP, Salehi HA, et al. Quantitation and physiological characterization of angiogenic vessels in mice - Effect of basic fibroblast growth factor vascular endothelial growth factor vascular permeability factor, and host microenvironment. Am J Pathol 1996, 149:59-71.
134. Yamada S, Mayadas TN, Yuan F, et al. Rolling in P-selectin-deficient mice is reduced but not eliminated in the dorsal skin. Blood 1995, 86:3487-3492.
135. Melder RJ, Brownell AL, Shoup TM, et al. Imaging of activated natural killer cells in mice by positron emission tomography: preferential uptake in tumors. Cancer Res 1993, 53:5867-5871.
136. Melder RJ, Jain RK Reduction of rigidity in human activated natural killer cells by thioglycollate treatment. J Immunol Methods 1994, 175:69-77.
137. Melder RJ, Jain RK Kinetics of interleukin-2 induced changes in rigidity of human natural killer cells. Cell Biophys 1992, 20:161-176.
138. Sasaki A, Jain RK, Maghazachi AA, et al. Low deformability of lymphokine-activated killer cells as a possible determinant of in vivo distribution. Cancer Res 1989, 49:3742-3746.
139. Melder RJ, Salehi HA, Jain RK Interaction of activated natural killer cells with normal and tumor vessels in cranial windows in mice. Microvasc Res 1995, 50:35-44.
140. Munn LL, Melder RJ, Jain RK Analysis of cell flux in the parallel plate flow chamber: implications for cell capture studies. Biophys J 1994, 67:889-895.
141. Munn LL, Koenig GC, Jain RK, et al. Kinetics of adhesion molecule expression and spatial organization using targeted sampling fluorometry. Biotechniques 1995, 19:622-631.
142. Sasaki A, Melder RJ, Whiteside TL, et al. Preferential localization of human adherent lymphokine-activated killer cells in tumor microcirculation. J Natl Cancer Inst 1991, 83:433-437.
143. Melder RJ, Koenig GC, Munn LL, et al. Adhesion of activated natural killer cells to tumor necrosis factor-alpha-treated endothelium under physiological flow conditions. Nat Immun 1996, 15:154-163.
144. Gamble JR, Khew-Goodall Y, Vadas MA Transforming growth factor-beta inhibits E-selectin expression on human endothelial cells. J Immunol 1993, 150:4494-4503.
145. Gamble JR, Vadas MA Endothelial adhesiveness for blood neutrophils is inhibited by transforming growth factor-beta. Science 1988, 242:97-99.
146. Gamble JR, Vadas MA Endothelial cell adhesiveness for human T lymphocytes is inhibited by transforming growth factor-beta 1. J Immunol 1991, 146:1149-1154.
147. Jallal B, Powell J, Zachwieja J, et al. Suppression of tumor growth in vivo by local and systemic 90K level increase. Cancer Res 1995, 55:3223-3227.
148. Detmar M, Brown LF, Schon MP, et al. Increased microvascular density and enhanced leukocyte rolling and adhesion in the skin of VEGF transgenic mice. J Invest Dermatol 1998, 111:1-6.
149. Hanahan D, Coussens LM Accessories to the crime: functions of cells recruited to the tumor microenvironment. Cancer Cell 2012, 21:309-322.
150. Fukumura D, Xavier R, Sugiura T, et al. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94:715-725.
151. Jain RK, Fenton BT Intratumoral lymphatic vessels: a case of mistaken identity or malfunction?. J Natl Cancer Inst 2002, 94:417-421.
152. Padera TP, Kadambi A, di Tomaso E, et al. Lymphatic metastasis in the absence of functional intratumor lymphatics. Science 2002, 296:1883-1886.
153. Elenbaas B, Weinberg RA Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation. Exp Cell Res 2001, 264:169-184.
154. Jain RK Transport of molecules in the tumor interstitium: a review. Cancer Res 1987, 47:3039-3051.
155. Berk DA, Yuan F, Leunig M, et al. Fluorescence photobleaching with spatial Fourier analysis: measurement of diffusion in light-scattering media. Biophys J 1993, 65:2428-2436.
156. Brown E, McKee T, diTomaso E, et al. Dynamic imaging of collagen and its modulation in tumors in vivo using second-harmonic generation. Nat Med 2003, 9:796-800.
157. Chary SR, Jain RK Direct measurement of interstitial convection and diffusion of albumin in normal and neoplastic tissues by fluorescence photobleaching. Proc Natl Acad Sci U S A 1989, 86:5385-5389.
158. Chauhan VP, Lanning RM, Diop-Frimpong B, et al. Multiscale measurements distinguish cellular and interstitial hindrances to diffusion in vivo. Biophys J 2009, 97:330-336.
159. Davies CL, Berk DA, Pluen A, et al. Comparison of IgG diffusion and extracellular matrix composition in rhabdomyosarcomas grown in mice versus in vitro as spheroids reveals the role of host stromal cells. Br J Cancer 2002, 86:1639-1644.
160. Johnson EM, Berk DA, Jain RK, et al. Diffusion and partitioning of proteins in charged agarose gels. Biophys J 1995, 68:1561-1568.
161. Johnson EM, Berk DA, Jain RK, et al. Hindered diffusion in agarose gels: test of effective medium model. Biophys J 1996, 70:1017-1023.
162. Nugent LJ, Jain RK Extravascular diffusion in normal and neoplastic tissues. Cancer Res 1984, 44:238-244.
163. Pluen A, Boucher Y, Ramanujan S, et al. Role of tumor-host interactions in interstitial diffusion of macromolecules: cranial vs. subcutaneous tumors. Proc Natl Acad Sci U S A 2001, 98:4628-4633.
164. Pluen A, Netti PA, Jain RK, et al. Diffusion of macromolecules in agarose gels: comparison of linear and globular configurations. Biophys J 1999, 77:542-552.
165. Swabb EA, Wei J, Gullino PM Diffusion and Convection in Normal and Neoplastic Tissues. Cancer Res 1974, 34:2814-2822.
166. Boucher Y, Brekken C, Netti PA, et al. Intratumoral infusion of fluid: estimation of hydraulic conductivity and implications for the delivery of therapeutic agents. Br J Cancer 1998, 78:1442-1448.
167. Znati CA, Rosenstein M, McKee TD, et al. Irradiation reduces interstitial fluid transport and increases the collagen content in tumors. Clin Cancer Res 2003, 9:5508-5513.
168. Berk DA, Yuan F, Leunig M, et al. Direct in vivo measurement of targeted binding in a human tumor xenograft. Proc Natl Acad Sci U S A 1997, 94:1785-1790.
169. Diop-Frimpong B, Chauhan VP, Krane S, et al. Losartan inhibits collagen I synthesis and improves the distribution and efficacy of nanotherapeutics in tumors. Proc Natl Acad Sci U S A 2011, 108:2909-2914.
170. McKee TD, Grandi P, Mok W, et al. Degradation of fibrillar collagen in a human melanoma xenograft improves the efficacy of an oncolytic herpes simplex virus vector. Cancer Res 2006, 66:2509-2513.
171. Netti PA, Berk DA, Swartz MA, et al. Role of extracellular matrix assembly in interstitial transport in solid tumors. Cancer Res 2000, 60:2497-2503.
172. Ramanujan S, Pluen A, McKee TD, et al. Diffusion and convection in collagen gels: implications for transport in the tumor interstitium. Biophys J 2002, 83:1650-1660.
173. Stylianopoulos T, Poh MZ, Insin N, et al. Diffusion of particles in the extracellular matrix: the effect of repulsive electrostatic interactions. Biophys J 2010, 99:1342-1349.
174. Baxter LT, Jain RK Transport of fluid and macromolecules in tumors. I. Role of interstitial pressure and convection. Microvasc Res 1989, 37:77-104.
175. Baxter LT, Jain RK Transport of fluid and macromolecules in tumors. III. Role of binding and metabolism. Microvasc Res 1991, 41:5-23.
176. Juweid M, Neumann R, Paik C, et al. Micropharmacology of monoclonal antibodies in solid tumors: direct experimental evidence for a binding site barrier. Cancer Res 1992, 52:5144-5153.
177. Kaufman EN, Jain RK Quantification of transport and binding parameters using fluorescence recovery after photobleaching. Potential for in vivo applications. Biophys J 1990, 58:873-885.
178. Kaufman EN, Jain RK Measurement of mass transport and reaction parameters in bulk solution using photobleaching: Reaction limited binding regime. Biophys J 1991, 60:596-610.
179. Kaufman EN, Jain RK Effect of bivalent interaction upon apparent antibody affinity: experimental confirmation of theory using fluorescence photobleaching and implications for antibody binding assays. Cancer Res 1992, 52:4157-4167.
180. Kaufman EN, Jain RK In vitro measurement and screening of monoclonal antibody affinity using fluorescence photobleaching. J Immunol Methods 1992, 155:1-17.
181. Gullino PM Extracellular compartments of solid tumors. Cancer 1975, 327-354. Plenum, New York. F.F. Becker (Ed.).
182. Leu AJ, Berk DA, Lymboussaki A, et al. Absence of functional lymphatics within a murine sarcoma: a molecular and functional evaluation. Cancer Res 2000, 60:4324-4327.
183. Carreira CM, Nasser SM, di Tomaso E, et al. LYVE-1 is not restricted to the lymph vessels: Expression in normal liver blood sinusoids and down-regulation in human liver cancer and cirrhosis. Cancer Res 2001, 61:8079-8084.
184. Hoshida T, Isaka N, Hagendoorn J, et al. Imaging steps of lymphatic metastasis reveals that vascular endothelial growth factor-C increases metastasis by increasing delivery of cancer cells to lymph nodes: therapeutic implications. Cancer Res 2006, 66:8065-8075.
185. Alitalo K, Carmeliet P Molecular mechanisms of lymphangiogenesis in health and disease. Cancer Cell 2002, 1:219-227.
186. Jain RK, Padera TP Development. Lymphatics make the break. Science 2003, 299:209-210.
187. Oliver G, Detmar M The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev 2002, 16:773-783.
188. Gale NW, Thurston G, Hackett SF, et al. Angiopoietin-2 is required for postnatal angiogenesis and lymphatic patterning, and only the latter role is rescued by Angiopoietin-1. Dev Cell 2002, 3:411-423.
189. Jain RK, Padera TP Prevention and treatment of lymphatic metastasis by antilymphangiogenic therapy. J Natl Cancer Inst 2002, 94:785-787.
190. Padera TP, Stoll BR, So PT, et al. Conventional and high-speed intravital multiphoton laser scanning microscopy of microvasculature, lymphatics, and leukocyte-endothelial interactions. Mol Imaging 2002, 1:9-15.
191. Leu AJ, Berk DA, Yuan F, et al. Flow velocity in the superficial lymphatic network of the mouse tail. Am J Physiol 1994, 267:H1507-H1513.
192. Berk DA, Swartz MA, Leu AJ, et al. Transport in lymphatic capillaries. II. Microscopic velocity measurement with fluorescence photobleaching. Am J Physiol 1996, 270:H330-H337.
193. Swartz MA, Berk DA, Jain RK Transport in lymphatic capillaries. I. Macroscopic measurements using residence time distribution theory. Am J Physiol 1996, 270:H324-H329.
194. Jeltsch M, Kaipainen A, Joukov V, et al. Hyperplasia of lymphatic vessels in VEGF-C transgenic mice. Science 1997, 276:1423-1425.
195. Isaka N, Padera TP, Hagendoorn J, et al. Peritumor lymphatics induced by vascular endothelial growth factor-C exhibit abnormal function. Cancer Res 2004, 64:4400-4404.
196. Fukumura D, Duda DG, Munn LL, et al. Tumor microvasculature and microenvironment: novel insights through intravital imaging in pre-clinical models. Microcirculation 2010, 17:206-225.
197. Liao S, Cheng G, Conner DA, et al. Impaired lymphatic contraction associated with immunosuppression. Proc Natl Acad Sci U S A 2011, 108:18784-18789.
198. Boucher Y, Baxter LT, Jain RK Interstitial pressure gradients in tissue-isolated and subcutaneous tumors: implications for therapy. Cancer Res 1990, 50:4478-4484.
199. Boucher Y, Kirkwood JM, Opacic D, et al. Interstitial hypertension in superficial metastatic melanomas in humans. Cancer Res 1991, 51:6691-6694.
200. Roh HD, Boucher Y, Kalnicki S, et al. Interstitial hypertension in carcinoma of uterine cervix in patients: possible correlation with tumor oxygenation and radiation response. Cancer Res 1991, 51:6695-6698.
201. Boucher Y, Jain RK Microvascular pressure is the principal driving force for interstitial hypertension in solid tumors: implications for vascular collapse. Cancer Res 1992, 52:5110-5114.
202. Gutmann R, Leunig M, Feyh J, et al. Interstitial hypertension in head and neck tumors in patients: correlation with tumor size. Cancer Res 1992, 52:1993-1995.
203. Less JR, Posner MC, Boucher Y, et al. Interstitial hypertension in human breast and colorectal tumors. Cancer Res 1992, 52:6371-6374.
204. Curti BD, Urba WJ, Alvord WG, et al. Interstitial Pressure of Subcutaneous Nodules in Melanoma and Lymphoma Patients: Changes During Treatment. Cancer Research 1993, 53:2204-2207.
205. Arbit E, Lee J, DiResta GR Interstitial hypertension in human brain tumors: Possible role in peritumoral edema formulation. Intracranial Pressure 1994, 604-619. Spirnger-Verlag, Tokyo. H. Nagai, K. Kamiya, S. Ishi (Eds.).
206. Nathanson SD, Nelson L Interstitial Fluid Pressure in Breast-Cancer, Benign Breast Conditions, and Breast Parenchyma. Annals of Surgical Oncology 1994, 1:333-338.
207. Boucher Y, Lee I, Jain RK Lack of general correlation between interstitial fluid pressure and oxygen partial pressure in solid tumors. Microvasc Res 1995, 50:175-182.
208. Boucher Y, Salehi H, Witwer B, et al. Interstitial fluid pressure in intracranial tumours in patients and in rodents. Br J Cancer 1997, 75:829-836.
209. Milosevic M, Fyles A, Hedley D, et al. Interstitial fluid pressure predicts survival in patients with cervix cancer independent of clinical prognostic factors and tumor: Oxygen measurements. Cancer Res 2001, 61:6400-6405.
210. Boucher Y, Leunig M, Jain RK Tumor angiogenesis and interstitial hypertension. Cancer Res 1996, 56:4264-4266.
211. Lee CG, Heijn M, di Tomaso E, et al. Anti-Vascular endothelial growth factor treatment augments tumor radiation response under normoxic or hypoxic conditions. Cancer Res 2000, 60:5565-5570.
212. Tong RT, Boucher Y, Kozin SV, et al. Vascular normalization by vascular endothelial growth factor receptor 2 blockade induces a pressure gradient across the vasculature and improves drug penetration in tumors. Cancer Res 2004, 64:3731-3736.
213. DiResta GR, Lee J, Healey JH, et al. "Artificial lymphatic system": A new approach to reduce interstitial hypertension and increase blood flow, pH and pO(2) in solid tumors. Ann Biomed Eng 2000, 28:543-555.
214. Stohrer M, Boucher Y, Stangassinger M, et al. Oncotic pressure in solid tumors is elevated. Cancer Res 2000, 60:4251-4255.
215. Raut CP, Boucher Y, Duda DG, et al. Effects of sorafenib on intra-tumoral interstitial fluid pressure and circulating biomarkers in patients with refractory sarcomas (NCI protocol 6948). PLoS One 2012, 7:e26331.
216. Willett CG, Boucher Y, di Tomaso E, et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med 2004, 10:145-147.
217. Willett CG, Boucher Y, Duda DG, et al. Surrogate markers for antiangiogenic therapy and dose-limiting toxicities for bevacizumab with radiation and chemotherapy: continued experience of a phase I trial in rectal cancer patients. J Clin Oncol 2005, 23:8136-8139.
218. Willett CG, Duda DG, di Tomaso E, et al. Efficacy, safety, and biomarkers of neoadjuvant bevacizumab, radiation therapy, and fluorouracil in rectal cancer: a multidisciplinary phase II study. J Clin Oncol 2009, 27:3020-3026.
219. Netti PA, Baxter LT, Boucher Y, et al. Time-dependent behavior of interstitial fluid pressure in solid tumors: implications for drug delivery. Cancer Res 1995, 55:5451-5458.
220. Netti PA, Hamberg LM, Babich JW, et al. Enhancement of fluid filtration across tumor vessels: implication for delivery of macromolecules. Proc Natl Acad Sci U S A 1999, 96:3137-3142.
221. Zlotecki RA, Boucher Y, Lee I, et al. Effect of angiotensin II induced hypertension on tumor blood flow and interstitial fluid pressure. Cancer Res 1993, 53:2466-2468.
222. Butler TP, Grantham FH, Gullino PM Bulk Transfer of Fluid in Interstitial Compartment of Mammary Tumors. Cancer Res 1975, 35:3084-3088.
223. Jain RK, Tong RT, Munn LL Effect of vascular normalization by antiangiogenic therapy on interstitial hypertension, peritumor edema, and lymphatic metastasis: insights from a mathematical model. Cancer Res 2007, 67:2729-2735.
224. Krogh A The Anatomy and Physiology of Capillaries 1922, Yale University Press, New York.
225. Thomlinson RH, Gray LH The histological structure of some human lung cancers and the possible implications for radiotherapy. Br J Cancer 1955, 9:539-549.
226. Helmlinger G, Yuan F, Dellian M, et al. Interstitial pH and pO2 gradients in solid tumors in vivo: high-resolution measurements reveal a lack of correlation. Nat Med 1997, 3:177-182.
227. Torres-Filho IP, Leunig M, Yuan F, et al. Noninvasive measurement of microvascular and interstitial oxygen profiles in a human tumor in SCID mice. Proc Natl Acad Sci U S A 1994, 91:2081-2085.
228. Brown JM, Giaccia AJ The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 1998, 58:1408-1416.
229. Dewhirst MW Concepts of oxygen transport at the microcirculatory level. Semin Rad Oncol 1998, 8:143-150.
230. Helmlinger G, Sckell A, Dellian M, et al. Acid production in glycolysis-impaired tumors provides new insights into tumor metabolism. Clin Cancer Res 2002, 8:1284-1291.
231. Harris AL Hypoxia: a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
232. Brown JM The hypoxic cell: a target for selective cancer therapy-eighteenth Bruce F. Cain Memorial Award lecture. Cancer Res 1999, 59:5863-5870.
233. Cowan DS, Tannock IF Factors that influence the penetration of methotrexate through solid tissue. Int J Cancer 2001, 91:120-125.
234. Kozin SV, Boucher Y, Hicklin DJ, et al. Vascular endothelial growth factor receptor-2-blocking antibody potentiates radiation-induced long-term control of human tumor xenografts. Cancer Res 2001, 61:39-44.
235. Vukovic V, Tannock IF Influence of low pH on cytotoxicity of paclitaxel, mitoxantrone and topotecan. Br J Cancer 1997, 75:1167-1172.
236. Jain RK: Normalizing tumor microenvironment to treat cancer: Bench to bedside to biomarkers. J Clin Oncol (in press).
237. Winkler F, Kozin SV, Tong RT, et al. Kinetics of vascular normalization by VEGFR2 blockade governs brain tumor response to radiation: role of oxygenation, angiopoietin-1, and matrix metalloproteinases. Cancer Cell 2004, 6:553-563.
238. Leite de Oliveira R, Deschoemaeker S, Henze AT, et al. Gene-targeting of phd2 improves tumor response to chemotherapy and prevents side-toxicity. Cancer Cell 2012, 22:263-277.
239. Mazzone M, Dettori D, Leite de Oliveira R, et al. Heterozygous deficiency of PHD2 restores tumor oxygenation and inhibits metastasis via endothelial normalization. Cell 2009, 136:839-851.
240. Carmeliet P, Dor Y, Herbert JM, et al. Role of HIF-1alpha in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis. Nature 1998, 394:485-490.
241. Harris AL Hypoxia-a key regulatory factor in tumour growth. Nat Rev Cancer 2002, 2:38-47.
242. Jain RK Barriers to drug delivery in solid tumors. Sci Am 1994, 271:58-65.
243. Jain RK The next frontier of molecular medicine: delivery of therapeutics. Nat Med 1998, 4:655-657.
244. McCormick F New-age drug meets resistance. Nature 2001, 412:281-282.
245. Jain RK, Duda DG, Clark JW, et al. Lessons from phase III clinical trials on anti-VEGF therapy for cancer. Nat Clin Pract Oncol 2006, 3:24-40.
246. Carmeliet P, Jain RK Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases. Nat Rev Drug Discov 2011, 10:417-427.
247. Batchelor TT, Duda DG, di Tomaso E, et al. Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol 2010, 28:2817-2823.
248. Batchelor TT, Sorensen AG, di Tomaso E, et al. AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell 2007, 11:83-95.
249. Sorensen AG, Batchelor TT, Zhang WT, et al. A "vascular normalization index" as potential mechanistic biomarker to predict survival after a single dose of cediranib in recurrent glioblastoma patients. Cancer Res 2009, 69:5296-5300.
250. Ince WL, Jubb AM, Holden SN, et al. Association of k-ras, b-raf, and p53 status with the treatment effect of bevacizumab. J Natl Cancer Inst 2005, 97:981-989.
251. Jubb AM, Hurwitz HI, Bai W, et al. Impact of vascular endothelial growth factor-A expression, thrombospondin-2 expression, and microvessel density on the treatment effect of bevacizumab in metastatic colorectal cancer. J Clin Oncol 2006, 24:217-227.
252. Zhu AX, Duda DG, Sahani DV, et al. HCC and angiogenesis: possible targets and future directions. Nat Rev Clin Oncol 2011, 8:292-301.
253. Duda DG, Willett CG, Ancukiewicz M, et al. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist 2010, 15:577-583.
254. Gerstner ER, Emblem KE, Chi AS, et al. Effects of cediranib, a VEGF signaling inhibitor, in combination with chemoradiation on tumor blood flow and survival in newly diagnosed glioblastoma. J Clin Oncol 2012, 30(suppl; abstr 2009).
255. Meyerhardt JA, Ancukiewicz M, Abrams TA, et al. Phase I study of cetuximab, irinotecan, and vandetanib (ZD6474) as therapy for patients with previously treated metastastic colorectal cancer. PLoS One 2012, 7:e38231.
256. Tolaney SM, Duda DG, Boucher Y, et al. A phase II study of preoperative (preop) bevacizumab (bev) followed by dose-dense (dd) doxorubicin (A)/cyclophosphamide (C)/paclitaxel (T) in combination with bev in HER2-negative operable breast cancer (BC). J Clin Oncol 2012, 30(suppl; abstr 1026).
257. Zhu AX, Ancukiewicz M, Supko JG, et al. Efficacy, safety, pharmacokinetics, and biomarkers of cediranib monotherapy in advanced hepatocellular carcinoma: A phase II study. Clin Cancer Res 2013, 19:1157-1166.
258. Xu L, Duda DG, di Tomaso E, et al. Direct evidence that bevacizumab, an anti-VEGF antibody, up-regulates SDF1alpha, CXCR4, CXCL6, and neuropilin 1 in tumors from patients with rectal cancer. Cancer Res 2009, 69:7905-7910.
259. Zhu AX, Sahani DV, Duda DG, et al. Efficacy, safety, and potential biomarkers of sunitinib monotherapy in advanced hepatocellular carcinoma: a phase II study. J Clin Oncol 2009, 27:3027-3035.
260. Duda DG, Kozin SV, Kirkpatrick ND, et al. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?. Clin Cancer Res 2011, 17:2074-2080.
261. Kamba T, Tam BY, Hashizume H, et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature. Am J Physiol Heart Circ Physiol 2006, 290:H560-H576.
262. Verheul HM, Pinedo HM Possible molecular mechanisms involved in the toxicity of angiogenesis inhibition. Nat Rev Cancer 2007, 7:475-485.